Beta Bionics, Inc. ( (BBNX) ) just unveiled an update.
On March 26, 2025, Beta Bionics, Inc. announced the appointment of Gerard Michel as a Class III director, with his term expiring at the 2028 annual meeting of stockholders. Mr. Michel, who has extensive experience in the biotechnology and pharmaceutical industries, will receive an annual cash retainer and restricted stock units as part of his compensation, with vesting conditions tied to his continuous service and potential company control changes.
More about Beta Bionics, Inc.
YTD Price Performance: -44.35%
Average Trading Volume: 648,598
For a thorough assessment of BBNX stock, go to TipRanks’ Stock Analysis page.